KRYS Financials Krystal Biotech, Inc.
10 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $389M | $205M | 0.0% | 41.5% | $189M | — | $496M |
| 2024 | $291M | $89M | 0.0% | 22.6% | $119M | — | $345M |
| 2023 | $51M | $11M | 0.0% | -216.2% | -$101M | — | $358M |
| 2022 | $0 | -$140M | — | — | -$154M | — | $162M |
| 2021 | $0 | -$70M | — | — | -$116M | — | $341M |
| 2020 | — | -$32M | — | — | -$41M | — | $268M |
| 2019 | — | -$19M | — | — | -$25M | — | $188M |
| 2018 | — | -$11M | — | — | -$12M | — | $104M |
| 2017 | — | -$8M | — | — | — | — | $50M |
| 2016 | — | -$1M | — | — | — | — | $2M |
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $116M | $56M | 0.0% | 46.1% | $73M | — | $501M |
| Dec '25 | $107M | $51M | 0.0% | 41.3% | $75M | — | $496M |
| Sep '25 | $98M | $79M | 0.0% | 42.3% | $38M | — | $393M |
| Jun '25 | $96M | $38M | 0.0% | 40.9% | $51M | — | $354M |
| Mar '25 | $88M | $36M | 0.0% | 41.1% | $25M | — | $309M |
| Dec '24 | $91M | $45M | 0.0% | 45.4% | $52M | — | $345M |
| Sep '24 | $84M | $27M | 0.0% | 26.8% | $58M | — | $374M |
| Jun '24 | $70M | $16M | 0.0% | 12.2% | -$5M | — | $346M |
| Mar '24 | $45M | $932000 | 0.0% | -14.8% | $15M | — | $359M |
| Dec '23 | $42M | $9M | 0.0% | 7.4% | -$9M | — | $358M |
| Sep '23 | $9M | $81M | 0.0% | -303.8% | -$23M | — | $373M |
| Jun '23 | $0 | -$33M | — | — | -$37M | — | $276M |
| Mar '23 | $0 | -$45M | — | — | -$32M | — | $141M |
| Dec '22 | $0 | -$32M | — | — | -$28M | — | $162M |
| Sep '22 | $0 | -$30M | — | — | -$34M | — | $186M |
| Jun '22 | — | -$28M | — | — | -$60M | — | $219M |
| Mar '22 | — | -$50M | — | — | -$33M | — | $269M |
| Dec '21 | — | -$22M | — | — | -$62M | — | $341M |
| Sep '21 | — | -$16M | — | — | -$28M | — | $287M |
| Jun '21 | — | -$16M | — | — | -$14M | — | $330M |
Valuation over time
How the market has priced KRYS against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-earnings ratio has fallen from 299.7× (Jan '24) to 51.8× (Jun '26).
- The price-to-sales ratio has fallen from 64.6× (Jan '24) to 27.3× (Jun '26).
Frequently asked questions
Is KRYS growing its revenue and profit?
See the revenue and net-income charts above for Krystal Biotech, Inc.'s multi-year trend.
How much debt does KRYS have?
As of FY2025, Krystal Biotech, Inc. reported — of total debt against $496M of cash.
What is KRYS's profit margin?
In FY2025, gross margin was —, operating margin 41.5%, and net margin 52.6%.
What is KRYS's P/E ratio?
As of Jun '26, Krystal Biotech, Inc. traded at a price-to-earnings ratio of about 51.8× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.